Children Ages 2 To <12 Experienced 94.8% Fewer Hereditary Angioedema (Hae) Attacks During Treatment With Takhzyro Over The 52-Week Treatment Period Compared To BaselineLate-Breaking Flash Talk Presentation Of Phase 3 Data Highlights Positive, Clinically Meaningful Results In Children <6 Years, Where No Long-Term Prophylaxis Treatment (Ltp) Is Currently ApprovedResults Are Consistent With The Favorable Efficacy And Safety Profile Of Takhzyro Observed In Adult And Adolescent Patients In Earlier StudiesGlobal Regulatory Filings To Begin In Fiscal Year 2022Takeda Today Announced Late-Breaking Data From The Phase 3 Spring Study (Nct04070326) Presented At The European Academy Of Allergy And Clinical Immunology (Eaaci) Hybrid Congress 2022, Demonstrating Positive Results Of Takhzyro
